REG - Solvonis Therapeutic - US Patent allowance for PTSD discovery programme

Solvonis TherapeuticsAnnouncement

07/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260107:nRSG8747Na&default-theme=true

RNS Number : 8747N  Solvonis Therapeutics PLC  07 January 2026

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

U.S. Patent allowance received for PTSD discovery programme

 

Demonstrating scientific and commercial significance

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel medicines for high-burden central nervous system ("CNS")
disorders, announces that it has received a Notice of Allowance (the
"Allowance") from the United States Patent and Trademark Office ("USPTO") for
a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress
Disorder ("PTSD") discovery programme. One compound from this series is
currently being evaluated alongside other candidates, with a lead compound
expected to be selected in Q1 2026 in line with prior guidance.

 

The Allowance strengthens the intellectual property foundations of SVN-SDN-14
at an important stage as the programme advances toward lead-candidate
selection. In addition to this IP milestone, the Company is highlighting the
scientific significance of the newly protected compounds in addressing
long-standing challenges in the development of next-generation PTSD
therapeutics.

 

Scientific significance

SVN-SDN-14 is focused on developing serotonin ("SERT"), dopamine ("DAT") and
noradrenaline ("NET") modulators designed to support pro-social engagement and
improve the effectiveness of psychological therapy in PTSD.

 

While balanced modulation of these pathways is increasingly recognised as
therapeutically valuable, translating this biology into a practical medicine
has historically been difficult. Key challenges have included controlling
duration of action, managing variability between patients, and ensuring
compatibility with scalable, real-world clinical use.

 

The newly allowed patent covers a novel chemical series designed to retain the
core SERT, DAT and NET activity underpinning the programme, while introducing
greater pharmacological control through predictable metabolic deactivation.
This approach is intended to maintain therapeutic effects while improving
dosing flexibility, safety margins and overall suitability for clinical use.

 

In allowing the claims, the USPTO examiner concluded that no existing patents
or publications disclosed or suggested the claimed compounds, confirming the
novelty of the approach.

 

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "These
compounds are scientifically exciting because they address a long-standing
challenge in this field. They are designed to preserve the monoaminergic
profile that supports positive social engagement in therapy, while introducing
a level of pharmacokinetic control that has historically been difficult to
achieve. This increases our confidence that the core biology of SVN-SDN-14 can
be translated into a medicine that is practical to develop, regulate and
ultimately deploy."

 

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "This patent
allowance strengthens both the scientific and commercial foundations of our
PTSD programme. It reflects our strategy of combining rigorous neuroscience
with disciplined medicinal chemistry to build differentiated, scalable CNS
therapeutics."

 

 

Enquiries:

 Solvonis Therapeutics plc                                       Via Walbrook
 Anthony Tennyson, CEO & Executive Director

 Singer Capital Markets (Broker)                                 +44 (0) 20 7496 3000
 Phil Davies

 Walbrook PR (PR/IR advisers)  Tel: +44 (0)20 7933 8780 or solvonistherapeutics@walbrookpr.com
                               (mailto:solvonistherapeutics@walbrookpr.com)
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001
 Lianne Applegarth                                               Mob: +44 (0)7584 391 303
 Rachel Broad                                                    Mob: +44 (0)7747 515 393

 

 

About Solvonis Therapeutics plc

 

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system (CNS) disorders. Headquartered in London and listed on the main market
of the London Stock Exchange, Solvonis is advancing a differentiated pipeline
of repurposed and novel compounds across addiction, psychiatry, and neurology.

 

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional discovery work
supporting expansion into broader CNS indications. Its lead asset, SVN-001, is
currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for
a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical
PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes built
on a dedicated compound library to identify new small-molecule modulators of
key neurotransmitter systems. This platform enables efficient early-stage
innovation and supports the Company's integrated approach to developing
therapies across its three strategic pillars.

 

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to deliver sustained value
through innovation in CNS therapeutics.

solvonis.com (https://solvonis.com) | LinkedIn
(http://www.linkedin.com/company/solvonis-tx) | X (Twitter)
(https://x.com/Solvonis)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASFKELSKEFA



            Copyright 2019 Regulatory News Service, all rights reserved